2024-03-28T14:54:57Zhttp://uvadoc.uva.es/oai/requestoai:uvadoc.uva.es:10324/420602022-02-01T10:43:57Zcom_10324_1181com_10324_931com_10324_894col_10324_1387
Tellería Orriols, Juan José
Blanco Quirós, Alfredo
Muntión, Sandra
Garrote Adrados, José Antonio
Arranz Sanz, Eduardo
Armentia Medina, Alicia
Díez, Ignacio
Castro, Jesús
2020-09-01T09:45:07Z
2020-09-01T09:45:07Z
2006
Respiratory Medicine, 2006, Volume 100, n. 6, p.1072-1078
0954-6111
http://uvadoc.uva.es/handle/10324/42060
10.1016/j.rmed.2005.09.028
1072
6
1078
Respiratory Medicine
100
The study of determinants of asthma is a subject of much interest currently, especially the pharmacogenetic aspects of asthma management. Genetic polymorphisms affecting amino-acids at positions 16 and 27 within β2-adrenoceptor (β2AR) gene have been implicated in the asthma phenotypes and influence on the variability observed in response to use of bronchodilator agents used in the treatment of asthma. Whether these polymorphisms alter the bronchoprotection response to -agonist treatment in Spanish asthmatic population is unknown. The aim of this study was to investigate whether genetic polymorphisms within β2AR gene modulate the clinical outcomes of the individual response to β2-agonist therapy and the development of desensitization in Spanish asthmatic patients.
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© Elsevier
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Tachyphylaxis to β2-agonists in Spanish asthmatic patients could be modulated by β2-adrenoceptor gene polymorphisms
info:eu-repo/semantics/article